Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TETON-2 inhaled treprostinil in idiopathic pulmonary fibrosis
NL-OMON59231Phase 3Completed
- Sponsor
- United Therapeutics Corporation
- Start
- Jul 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of treprostinil in idiopathic pulmonary fibrosis (IPF), sponsored by United Therapeutics Corporation. Primary endpoint: Change in absolute forced vital capacity at Week 52. Started Jul 2023; status: completed.
02
Drugs
treprostinil
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NL-OMON59231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59231.